Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- FDMT
- Price
- 8.09
- Stock movement up
- +0.40 (5.20%)
- Company name
- 4D Molecular Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 462.22M
- Ent value
- 468.67M
- Price/Sales
- 3851.86
- Price/Book
- 1.25
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -5.41%
- 1 year return (CAGR)
- 73.23%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
FDMT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3851.86 |
| Price to Book | 1.25 |
| EV to Sales | 3905.56 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 57.14M |
| EPS (TTM) | -3.73 |
| FCF per share (TTM) | -3.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 120.00K |
| Gross profit (TTM) | -96.85M |
| Operating income (TTM) | -230.38M |
| Net income (TTM) | -209.18M |
| EPS (TTM) | -3.73 |
| EPS (1y forward) | -3.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -80710.83% |
| Operating margin (TTM) | -191982.50% |
| Profit margin (TTM) | -174314.17% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 48.55M |
| Net receivables | 0.00 |
| Total current assets | 312.38M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 55.12M |
| Total assets | 423.98M |
| Accounts payable | 6.86M |
| Short/Current long term debt | 22.26M |
| Total current liabilities | 37.11M |
| Total liabilities | 55.00M |
| Shareholder's equity | 368.98M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -183.50M |
| Capital expenditures (TTM) | 1.74M |
| Free cash flow (TTM) | -185.23M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -56.69% |
| Return on Assets | -49.34% |
| Return on Invested Capital | -55.83% |
| Cash Return on Invested Capital | -49.44% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.70 |
| Daily high | 8.19 |
| Daily low | 7.63 |
| Daily Volume | 556K |
| All-time high | 52.67 |
| 1y analyst estimate | 33.11 |
| Beta | 2.95 |
| EPS (TTM) | -3.73 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 27 Feb 2026 |
Downside potential
Loading...
Downside potential data
| FDMT | S&P500 | |
| Current price drop from All-time high | -84.64% | -0.89% |
| Highest price drop | -95.23% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -87.72% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
462.22M
Marketcap category
Small-cap
Description
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.
Employees
227
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page